Stability-indicating methods for determination of hydrochlorothiazide in combination with some antihypertensive drugs in the presence of its main impurities
- 22 Downloads
Hydrochlorothiazide (HCTZ) is potent diuretic that used alone or in combination with other antihypertensive drugs such as labetalol hydrochloride (Lab) or nebivolol hydrochloride (Neb) to control moderate to severe hypertension. As there is no published method for simultaneous determination of HCTZ and Lab (mixture Ι) or Neb (mixture ΙΙ) in pharmaceutical formulations in presence of HCTZ-related impurities, it was important to develop validated stability-indicating HPLC methods for analysis of these mixtures in quality control laboratories. These methods based on gradient RP-HPLC separation of mixture Ι at 215 nm using acetonitrile:0.1% triethylamine pH = 2 (12:88 v/v) as mobile phase at flow rate 1.0 mL/min using Promosil C18 (150 mm × 4.6 mm i.d.; 5 µm) column. While mixture ΙΙ separation was performed at 220 nm using BDS Hypersil C18 (250 mm × 4.6 mm i.d.; 5 µm) column with mobile phase of acetonitrile:phosphate buffer pH = 3 (15:85 v/v) at flow rate 1.0 mL/min. The responses were linear over concentration ranges 2.0–100 µg/mL (r = 0.9997) and 1.0–100 µg/mL (r = 0.9998) with mean recoveries 100.16% and 100.43% of Lab and HCTZ, respectively meanwhile 5.0–100 µg/mL (r = 0.9997) and 2.0–100 µg/mL (r = 0.9996) with mean recoveries 99.99% and 100.63% of Neb and HCTZ, respectively. Methods were validated according to ICH guidelines; the results were statistically compared with the company methods and there was no significant difference. The proposed methods have the advantages of being stability-indicating and time saving with low solvent consumption which favors their usage in quality control routine analysis of selected mixtures in their pharmaceutical formulations.
KeywordsChromatography Hydrochlorothiazide Impurities Labetalol hydrochloride Nebivolol hydrochloride
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest, financial or otherwise.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.N.As. Joel, C. Shantaram, I.J. Naresh, Res. Pharm. Biomed. Sci. 4, 380–384 (2013). https://doi.org/10.13179/canchemtrans.2013.01.01.0014 Google Scholar
- 4.N. Rahman, S.K. Haque, Int. J. Biomed. Anal. 4, 140–146 (2008)Google Scholar
- 10.S.L. Tamisier-Karolak, M.A. Stenger, A. Bommart, Electrophoresis 20, 2656–2663 (1999). https://doi.org/10.1002/(SICI)1522-2683(19990901)20:13%3C2656::AID-ELPS2656%3E3.0.CO;2-6 CrossRefGoogle Scholar
- 14.A. Radi, Z. El-Sherif, A. Wassel, Chem. Papers 58, 242–246 (2004)Google Scholar
- 15.A.G. Gilman, T.W. Rall, A.S. Nies, P. Taylor (eds.), The Pharmacological Basis of Therapeutics, 8th edn. (Pergamon Press, Oxford, 1990), p. 847Google Scholar
- 17.A. Manzoor, Y.N. Manohara, M.C. Ravi, Int. J. Chem. Tech. Res. 4, 328–336 (2012)Google Scholar
- 18.S.A. Patel, H.M. Patel, Int. J. PFR 2, 28–38 (2012)Google Scholar
- 19.K.V. Shah, P.R. Tirgar, D.B. Sheth, T.R. Desai, Int. J. Pharm. Sci. 2, 27–35 (2011)Google Scholar
- 20.R.K. Patel, J.B. Patel, Int. J. APBC. 1, 496–502 (2012)Google Scholar
- 21.S.C. Sweetman, B. Pharm, F.R. Pharm, S. Martindale, The Complete Drug Reference, 36th edn. (The Pharmaceutical Press, London, 2009), pp. 1307–1311Google Scholar
- 22.D. Ivanović, M. Medenica, B. Jančić, N. Knežević, A. Malenović, J. Milić, Acta Chromatogr. 18, 143–156 (2007)Google Scholar
- 24.A.T. Hemke, M.V. Bhure, K.S. Chouhan, K.R. Gupta, S.G. Wadodkar, ECHEM 7, 1156–1161 (2010)Google Scholar
- 27.U.S. Pharmacopoeia 40th edn. (U.S. Pharmacopeial Convention, Inc., Rockville, 2017)Google Scholar
- 28.ICH Validation of analytical procedures: text and methodology Q2 (R1), in International Conference on Harmonization (2005)Google Scholar